Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Richard Doll Building, University of Oxford

EMPA-KIDNEY is a clinical trial initiated by scientists based at the Medical Research Council Population Health Research Unit (PHRU), which is part of the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU) at the University of Oxford. The Oxford team was supported by an academic collaboration spanning eight countries, including the United States, Canada, Germany, China, Japan, Malaysia, Italy and the United Kingdom. EMPA-KIDNEY recruited over 6000 volunteers with chronic kidney disease to participate in the trial, as well as many kidney, diabetes and other medical speciality healthcare teams around the world who helped make the study possible.

Information about the study for people with chronic kidney disease can be found in the FAQ section.

Information about the study and empagliflozin for healthcare professionals can be found in the Professionals section.